PR Newswire · Nov 2025
CAHF named Darmiyan its preferred provider, giving more than 1,300 member facilities access to BrainSee for early brain-health assessment and dementia prevention.
Company research
Public company, workplace, funding, and market signals
Overview
Darmiyan is a San Francisco-based neurotechnology and public-health company that uses AI plus brain MRI analysis to screen and monitor brain health, with BrainSee as its flagship FDA-approved prognostic test for estimating progression from amnestic mild cognitive impairment to Alzheimer’s dementia.
Primary product
BrainSee
Founded
2016
Headquarters
San Francisco, California, United States
Team size
11-50
Work style
Onsite
Industry
Public Health
Sub-industry
Neurotechnology / brain health diagnostics
Offices
San Francisco, California, United States
Berkeley, California, United States (1425 Berkeley Way)
Toronto, Ontario, Canada (business development office reported in founder bios)
Business model
B2B clinical software
Physician-facing diagnostic service
Healthcare provider / enterprise licensing
Funding
Stage
Series A
Total raised
$14.7M
Latest round
Venture Round · Oct 2023
Latest amount
$3.5M
People & investors
Leadership
Founder & CEO
Chief Medical & Technology Officer & Co-founder
Co-founder, Product Consultant
Head of Operations
Head of Analytics and Innovation
Director of Operations and Patient Safety
Manager / Business Consultant
Work & culture
Mission-driven, research-heavy team of neuroscientists, data scientists, clinicians, and patient advocates focused on high accuracy, non-invasiveness, seamless integration, and global accessibility in brain health.
Work style
Onsite
Compensation
Public salary estimates suggest roughly $117.5k average annual pay in the U.S., with typical ranges around $103.5k-$132.7k; official compensation bands were not published.
Benefits
401(k)
time off
comprehensive benefits package
Product & market
Pricing
Not publicly disclosed; BrainSee is sold through a physician-facing portal and third-party sources suggest per-test style pricing.
Differentiators
- —FDA-approved De Novo prognostic test for Alzheimer’s progression
- —Non-invasive MRI + cognitive assessment workflow
- —Predicts 5-year progression from aMCI to Alzheimer’s dementia
- —Patented DarmiScope / virtual microscope technology
- —Same-day / web-portal delivery into clinical workflow
- —Accessible to primary-care physicians, not only specialists
Technology
AI / machine learning
medical image processing
brain imaging software
MRI analysis
cloud data science
HIPAA-compliant web portal
Mailchimp
Figma
Adobe
Calendly
Customers
Physicians treating amnestic mild cognitive impairment
California Association of Health Facilities (CAHF)
Long-term care / skilled nursing facilities
Community clinics and hospitals
Pharmaceutical companies
Clinical research organizations (CROs)
Competitors
C2N Diagnostics
Winterlight Labs
Canary Speech
Cortechs.ai
DiamiR
Optina
Radiabeam Systems
Big Health
Connected Mind
Scale & contact
Estimated revenue
~$1.6M ARR (GetLatka) to $10M-$25M annual revenue (LeadIQ/other third-party estimates); public estimates conflict.
Estimated monthly visits
813
Latest news
PR Newswire · May 2025
FDA approved a 7-year post-market study intended to further validate BrainSee’s safety and effectiveness in diverse populations.
PR Newswire · Dec 2024
Darmiyan said BrainSee and DarmiSpace would be used in the Medicare GUIDE dementia-care model to support early risk assessment and prevention.
PR Newswire · Jan 2024
Darmiyan announced FDA De Novo approval for BrainSee and described the product as a non-invasive, physician-accessible prognostic software tool.
Reportable / Newsfile · May 2021
FDA granted breakthrough status to BrainSee for non-invasive detection and monitoring of Alzheimer’s disease at the early stage of mild cognitive impairment.
Jobs and careers at Darmiyan
0 jobs at Darmiyan
No open positions
Check back later for new openings